ZESTORETIC (lisinopril and hydrochlorothiazide) by Almatica Pharma is mechanism of action lisinopril inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension, to lower blood pressure. First approved in 1989.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
ZESTORETIC is a fixed-dose combination of lisinopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic) administered orally as a tablet. It treats hypertension by inhibiting angiotensin-converting enzyme to reduce vasoconstriction and aldosterone secretion, while the diuretic component increases sodium and water excretion. This dual mechanism provides synergistic blood pressure reduction with potassium-sparing benefits compared to monotherapy.
Product approaching loss of exclusivity with modest Medicare utilization signals declining team investment in marketing and sales support.
Mechanism of Action Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the…
Thiazide Diuretic
Worked on ZESTORETIC at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moZESTORETIC career opportunities cluster in manufacturing, quality, and technical roles under current sponsor Almatica Pharma, reflecting a mature product requiring operational excellence rather than growth. Positions are stable but not expanding; career advancement depends on technical specialization in manufacturing or regulatory compliance rather than commercial or clinical innovation.
7 open roles linked to this drug